1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6888BC956E8E5ACAD0025877A004707E5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/new-portfolio-planning-study-examines-successes-failures-of-leading-brands-across-different-therapeutic-areas?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25Main






New portfolio planning study examines successes and failures of leading brands across different therapeutic areas

CHAPEL HILL, N.C., Jul. 29, 2020/PRNewswire/ -- As indications become more crowded, and the needs and influence of key stakeholders evolve, pharmaceutical and biotech companies need to meticulously build the new product planning framework to avoid costly missteps and ensure future launch success.

And in a world of new gene-based therapies, this challenge presents itself to many new products with methods of action that may work across conditions, indications, and organ systems. While some companies have succeeded in introducing multiple products for a common therapeutic area using the same method of action / technology platform, this approach is both resource-intensive and strategically challenging for launch teams.

To illustrate how drug platforms can give rise to strong tech / MOA-enabled product portfolios and market-leading franchises, Best Practices, LLC conducted this new “meta-analysis” of 22 of its benchmark studies.

“Strategic Portfolio Planning for Successful New Product and Drug Platform Positioning” is a new 179-page research study that draws upon primary as well as secondary benchmark studies probing technology platform and product portfolio management excellence.

According to this research, most important activities for engaging advocacy groups in portfolio planning include:

  • Creating alliances with patient advocacy groups (79% of organizations gave this high importance)
  • Building relationships with key patient advocates or celebrities (71% of organizations gave this high importance)
  • Disease state awareness campaigns and websites for/with patient groups (54% of organizations gave this high importance)

Key topics covered in this report include:

  • Strategic portfolio platforms
  • Novel tech / MOA market development
  • Portfolio management

The research includes six case studies of successful and unsuccessful drug launches, including Rituxan, Cymbalta, Byetta, Exubera, Januvia and Sovaldi.

For biopharma executives across the industry, this report spotlights a wealth of winning strategies, best practices and pitfalls to avoid for successful positioning of new products and drug platforms.

Download a complimentary report summary at: https://www.best-in-class.com/rw102.htm.



ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.